



Ridge Diagnostics, Inc.
MDDScore™ - First Blood Test for Depression at the
American Psychiatric Association Annual Meeting

San Diego, CA May 18, 2013 – Ridge Diagnostics, Inc., a neurodiagnostic company, announces the launch of MDDScore the first blood test to aid in diagnosing Major Depressive Disorder (MDD). Ridge will provide the science behind the MDDScore at the American Psychiatric Association’s (APA) annual meeting from May 18th to May 21st in San Francisco, California at The Convention Center.

Ridge Diagnostics’ APA exhibit can be located at **Booth # 708**. The company will discuss the availability of MDDScore™ to psychiatrists in the US and will also have available MDDScore’s latest clinical study results that demonstrate over 90% accuracy when compared to Standardized Diagnostic Interviews. MDDScore is the first depression blood test to offer psychiatrists and their patients a quantitative physiological measure of a person’s likelihood to have MDD.

James A. Smith, III, MD, Medical Director at Carolina Partners in Mental Health Care, and one of the first psychiatrists to use MDDScore, recently stated that with a wide variety of symptoms, diagnosing depression and getting patients the right treatment can mean a lot of trial and error.

“MDDScore more than anything else has given me an opportunity to hit it right on the nose,” Dr. Smith said.

Antidepressant drugs are the second most frequently prescribed medication in the US today where depression strikes over 19 million adults each year – more than coronary artery disease and AIDS. For the first time, objective biological test information about depression may aid physicians in the differential diagnosis of MDD, the selection of proper treatment and management for their patients.

“Ridge diligently prepared for the launch of MDDScore, and the data being presented at the APA meeting further illustrates the clinical importance of the MDDScore blood test in medicine today,” stated Lonna J. Williams, CEO of Ridge Diagnostics. “Our latest study demonstrates the enhanced benefit of MDDScore, in-conjunction with psychiatric assessment, providing patients with insight into their depression as a treatable disorder and which helps them minimize self-doubt and stigma.”

The MDDScore blood test provides clinicians with biological information derived from physiological changes associated with MDD. The addition of a quantitative, biological-basis assessment is intended to augment the current tools used for neuropsychiatric diagnosis and patient management.

MDDScore is available in most states and will be national by year-end.

Ridge Diagnostics, Inc. Ridge Diagnostics is a neurodiagnostic company developing and marketing blood-based tests to diagnose and monitor neuropsychiatric disorders. Ridge has commercialized the first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The portfolio of neurodiagnostic blood tests are based on a proprietary Human Biomarker Library and technology platform. The testing services are provided by the Ridge owned CLIA laboratory. The company is located in San Diego, CA and Research Triangle Park, NC. www.ridgedx.com

Contacts:

Investor Relations:

Ridge Diagnostics: Lonna J. Williams, CEO

800-578-7818 ex 101

lwilliams@ridgedx.com

Media Relations:

Ridge Diagnostics: Debora I. Demarest, Director of Corporate Communications

800-578-7818 ex 106

ddemarest@ridgedx.com